Amendments to the claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound of formula (I):



(I)

wherein:

one of Z_1, Z_2, Z_3, Z_4 and Z_5 is N, one is CR^{1a} and the remainder are CH , or

one or two of Z_1, Z_2, Z_3, Z_4 and Z_5 are independently CR^{1a} and the remainder are CH;

R^1 and R^{1a} are independently hydrogen; hydroxy; (C_{1-6})alkoxy unsubstituted or substituted by (C_{1-6})alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{1-6})alkoxy-substituted(C_{1-6})alkyl; halogen; (C_{1-6})alkyl; (C_{1-6})alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C_{1-6})alkylsulphonyl; (C_{1-6})alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups;

provided that when Z_1, Z_2, Z_3, Z_4 and Z_5 are CR^{1a} or CH, then R^1 is not hydrogen;

W_1, W_2, W_3 and W_4 are each independently selected from N or CR^3;

each R^3 is independently selected from:
hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C_{1-6})alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

A is $(CRR)_n$;
B is $(CRR)_m$, C=O, or SO_2;
n is 1 or 2;
m is 1 or 2
provided that when n is 1, m is 2; when n is 2, m is 1; and when B is C=O or SO_2 then n is 2;

each R is independently selected from
hydrogen; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C_{1-6})alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

R^2 is a substituted or ~~unsubstitued bicyclic carbocyclic or~~ unsubstituted bicyclic heterocyclic ring system of formula (A):



(A)

containing up to four heteroatoms in each ring in which

ring (a) is substituted or unsubstituted pyridine ~~aromatic~~ and ring (b) is substituted or unsubstituted non-aromatic ~~aromatic or non-aromatic~~;

X^1 is C;

X^2 is N or CR^4, ~~NR^6, O, S(O)x, CO, CR^4 or CR^4R^5~~;

X^3 and X^4 are ~~each independently N or~~ C;

Y^1 is a ~~1 to~~ 2 atom linker group each atom of which is independently selected from N and CR^4;

Y^2 is a 4 atom linker group having S bonded to X^4 and NHCO bonded via N to X^3 in which the other atom is CR^4R^5 ~~2 to 6 atom linker group, each atom of Y^2 being independently selected from N, NR^6, O, S(O)x, CO, CR^4 and CR^4R^5~~;

each R^4 and R^5 is independently selected from: hydrogen; (C_{1-4})alkylthio; halo; carboxy(C_{1-4})alkyl; halo(C_{1-4})alkoxy; halo(C_{1-4})alkyl; (C_{1-4})alkyl; (C_{2-4})alkenyl; (C_{1-4})alkoxycarbonyl; formyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; (C_{1-4})alkylcarbonyloxy; (C_{1-4})alkoxycarbonyl(C_{1-4})alkyl; hydroxy; hydroxy(C_{1-4})alkyl; mercapto(C_{1-4})alkyl; (C_{1-4})alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; (C_{2-6})alkenyl; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; or aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; aryl(C_{1-4})alkoxy; or R^4 and R^5 may together represent oxo; and

each R^6 is independently hydrogen; trifluoromethyl; (C_{1-4})alkyl unsubstituted or substituted by hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, halo or trifluoromethyl; (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; arylcarbonyl; heteroarylcarbonyl; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; formyl; (C_{1-6})alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl~~; and~~

~~each x is independently 0, 1, or 2~~;

or a pharmaceutically acceptable salt thereof.

2. (Original) A compound according to claim 1 wherein Z_5 is CH or N, Z_3 is CH or CF and Z_1, Z_2 and Z_4 are each CH, or Z_1 is N, Z_3 is CH or CF and Z_2, Z_4 and Z_5 are each CH.

3. (Original) A compound according to claim 1 wherein R^1 is methoxy and R^{1a} is H or when Z_3 is CR^{1a} it may be C-F.

4. (Original) A compound according to claim 1 wherein:

a) W_1-W_4 are independently CR^3;

b) W_1, W_3 and W_4 are N and W_2 is CR^3;

c) W_2 is N and W_1, W_3 and W_4 are independently CR^3;

d) W_3 is N and W_1, W_2 and W_4 are independently CR^3; or

e) W_4 is N and W_1-W_3 are independently CR^3.

5. (Original) A compound according to claim 1 wherein R^3 is independently selected from hydrogen, substituted and unsubstituted (C_{1-6})alkoxy, and NH_2.

6. (Original) A compound according to claim 1 wherein R is independently selected from hydrogen, substituted and unsubstituted (C_{1-6})alkyl, $CONH_2$, COOH, hydroxy, halogen, and substituted and unsubstituted (C_{1-6})alkoxy.

7. Canceled.

8. (Currently amended) A compound according to claim 1 wherein R^2 is selected from

4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one-6-yl and 1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one-7-yl

~~4*H*-benzo[1,4]thiazin-3-one-6-yl,~~

~~4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one-6-yl,~~

~~4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one-6-yl,~~

~~1,2,3,4-tetrahydro-[1,8]naphthyridine-7-yl,~~

~~1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one-7-yl,~~

~~4*H*-benzo[1,4]oxazin-3-one-6-yl, and~~
~~6-fluoro-2,3-dihydrobenzo[1,4]dioxine-7-yl~~.

9. (Currently amended) A compound according to claim 1 which is:

~~6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4*H*-benzo[1,4]thiazin-3-one;~~

6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

~~6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;~~

~~3-Oxo-3,4-dihydro-2*H*-benzo[1,4]thiazine-6-sulfonic acid [2-[4-(6-methoxy-[1,5]naphthyridin-4-yl)phenyl]ethyl}amide;~~

~~{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethyl} (5,6,7,8-tetrahydro[1,8]naphthyridin-2-ylmethyl)amine;~~

~~6-{[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]methyl}-4*H*-benzo[1,4]thiazin-3-one;~~

7-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-1*H*-pyrido[3,2-*b*][1,4]thiazin-2-one;

~~6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-benzo[1,4]oxazin-3-one;~~

~~6-{2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)benzylamino]ethyl}-4*H*-benzo[1,4]thiazin-3-one;~~

~~(7-Fluoro-2,3-dihydrobenzo[1,4]dioxin-6-ylmethyl){2-[6-(6-methoxy[1,5]naphthyridin-4-yl)[1,2,4]triazin-3-yl]ethyl}amine;~~

~~6-({2-[4-(6-Methoxyquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;~~

6-({2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[4-(8-Fluoro-6-methoxyquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[5-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-2-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

~~6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]oxazin-3-one;~~

~~*N*-(2,3-dihydro[1,4]dioxino[2,3-*c*]pyridin-7-ylmethyl)-2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethanamine;~~

~~*N*-(2,3-dihydro[1,4]dioxino[2,3-*c*]pyridin-7-ylmethyl)-2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethanamine;~~

N-(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide; and

N-(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide;

or a pharmaceutically acceptable salt thereof.

10. (Original) A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

11. (Original) A method of treating bacterial infections in mammals which comprises the administration to a mammal in need thereof an effective amount of a compound according to claim 1.

12. (New) A compound according to claim 1 wherein X^2 is N and Y^1 is a 2 atom linker group each atom of which is independently CR^4.